Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02981628||Active, not recruiting||Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia||
||Other / NIH||
||56||All||1 Year to 21 Years (Child, Adult)||NCT02981628||AALL1621
|June 5, 2017||June 2019||June 2019||December 5, 2016||December 26, 2017||